LLY

1,163.9

+2.99%↑

JNJ

232.44

-0.09%↓

ABBV

223.95

-1.49%↓

UNH

402.63

+0.58%↑

MRK

120.95

+0.02%↑

LLY

1,163.9

+2.99%↑

JNJ

232.44

-0.09%↓

ABBV

223.95

-1.49%↓

UNH

402.63

+0.58%↑

MRK

120.95

+0.02%↑

LLY

1,163.9

+2.99%↑

JNJ

232.44

-0.09%↓

ABBV

223.95

-1.49%↓

UNH

402.63

+0.58%↑

MRK

120.95

+0.02%↑

LLY

1,163.9

+2.99%↑

JNJ

232.44

-0.09%↓

ABBV

223.95

-1.49%↓

UNH

402.63

+0.58%↑

MRK

120.95

+0.02%↑

LLY

1,163.9

+2.99%↑

JNJ

232.44

-0.09%↓

ABBV

223.95

-1.49%↓

UNH

402.63

+0.58%↑

MRK

120.95

+0.02%↑

Home・Akciju saraksts・United Therapeutics Corp

United Therapeutics Corp

Atvērts

SektorsVeselības aprūpe

547.1 -0.04

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

543.92

Max

550.22

Galvenie mērījumi
By Trading Economics
Ienākumi	-89M 275M
Pārdošana	-8.7M 782M
P/E Sektora vidējais	20.134 49.888
EPS	5.82
Peļņas marža	35.176
Darbinieki	1,400
EBITDA	-176M 348M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt (spēcīgs)
Prognoze 12 mēnešiem	+21.1% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 29. jūl.

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	-1.5B 23B
Iepriekšējā atvēršanas cena	547.14
Iepriekšējā slēgšanas cena	547.1

Ziņu noskaņojums

By Acuity

50%

139 / 344 Rangs Healthcare

United Therapeutics Corp Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 5. jūn. 19:20 UTC

Galvenie tirgus virzītāji

Meta Platforms Slips on Report of Plans for Multibillion-Dollar Offering to Fund AI Buildout

2026. g. 7. jūn. 23:46 UTC

Tirgus saruna

Nikkei Likely to Fall After U.S. Tech Selloff -- Market Talk

2026. g. 7. jūn. 23:36 UTC

Tirgus saruna

Oil Prices Rise Amid Escalating Supply Disruption Concerns -- Market Talk

2026. g. 7. jūn. 18:00 UTC

Peļņas

Inflation Readings, Oracle Earnings, the SpaceX IPO, and More to Watch This Week -- Barrons.com

2026. g. 6. jūn. 12:40 UTC

Iegādes, apvienošanās, pārņemšana

Correction to Texas Billionaires Article America's Resort -- WSJ

2026. g. 6. jūn. 08:20 UTC

Tirgus saruna

Tech, Media & Telecom Roundup: Market Talk

2026. g. 6. jūn. 08:20 UTC

Tirgus saruna

Financial Services Roundup: Market Talk

2026. g. 6. jūn. 04:15 UTC

Tirgus saruna

Global Commodities Roundup: Market Talk

2026. g. 6. jūn. 00:14 UTC

Iegādes, apvienošanās, pārņemšana

4 Arm Execs Sold $26 Million in Stock, but They Missed a High -- Barrons.com

2026. g. 5. jūn. 21:27 UTC

Peļņas

Carnage in Chip Stocks Hits Extra Hard in Top-Heavy Market -- WSJ

2026. g. 5. jūn. 20:50 UTC

Tirgus saruna

Tech, Media & Telecom Roundup: Market Talk

2026. g. 5. jūn. 20:50 UTC

Tirgus saruna

Financial Services Roundup: Market Talk

2026. g. 5. jūn. 20:20 UTC

Iegādes, apvienošanās, pārņemšana

Altice France Group Had Granted Initial Exclusivity Period to Consortium Until May 15, Which Was Then Extended to June 5

2026. g. 5. jūn. 20:19 UTC

Iegādes, apvienošanās, pārņemšana

Altice France Group, Bouygues Telecom, Free-iliad Group, Orange Exclusivity Period Extended by 48 Hours

2026. g. 5. jūn. 20:15 UTC

Tirgus saruna

Global Commodities Roundup: Market Talk

2026. g. 5. jūn. 19:26 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 5. jūn. 19:26 UTC

Tirgus saruna

Hog Futures Tumble to Close Week -- Market Talk

2026. g. 5. jūn. 19:10 UTC

Tirgus saruna

Canada's GDP Targets From AI-Related Spending Require Second Look -- Market Talk

2026. g. 5. jūn. 19:03 UTC

Tirgus saruna

Oil Falls As Market Holds Out Hope for End to Conflict -- Market Talk

2026. g. 5. jūn. 18:59 UTC

Tirgus saruna

U.S. Natural-Gas Futures Pull Back After Gains -- Market Talk

2026. g. 5. jūn. 18:47 UTC

Tirgus saruna

Canada's Labor Market 'Retains Some Weakness' Despite Stellar May Report -- Market Talk

2026. g. 5. jūn. 18:34 UTC

Tirgus saruna

Hyperliquid ETFs Have Inflows Despite Crypto Weakness -- Market Talk

2026. g. 5. jūn. 18:33 UTC

Iegādes, apvienošanās, pārņemšana

The U.S. Government Could Take a Stake in OpenAI. What That Means for Tech Stocks. -- Barrons.com

2026. g. 5. jūn. 17:50 UTC

Peļņas

Lululemon Slumps on Earnings. Bargain Hunters Beware. -- Barrons.com

2026. g. 5. jūn. 17:27 UTC

Tirgus saruna

U.S. Oil Rig Count Rises for 6th Straight Week -- Market Talk

2026. g. 5. jūn. 16:48 UTC

Iegādes, apvienošanās, pārņemšana

Ryan Cohen Is Ready to Talk About eBay. For Real. -- Barrons.com

2026. g. 5. jūn. 16:20 UTC

Tirgus saruna

Tech, Media & Telecom Roundup: Market Talk

2026. g. 5. jūn. 16:20 UTC

Tirgus saruna

Financial Services Roundup: Market Talk

2026. g. 5. jūn. 16:20 UTC

Tirgus saruna

Health Care Roundup: Market Talk

2026. g. 5. jūn. 16:15 UTC

Tirgus saruna

Global Commodities Roundup: Market Talk

Salīdzinājums

Cenas izmaiņa

United Therapeutics Corp Prognoze

Cenas mērķis

By TipRanks

21.1% augšup

Prognoze 12 mēnešiem

Vidējais 665.9 USD 21.1%

Augstākais 738 USD

Zemākais 516 USD

Pamatojoties uz 10 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi United Therapeutics Corp — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

10 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 10 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam United Therapeutics Corp — pēdējo 3 mēnešu laikā.

Noskaņojums

By Acuity

139 / 344 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par United Therapeutics Corp

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.